Effect of Interferon-α on cognitive functioning in patients with chronic hepatitis C
Treatment with interferon-alpha (IFN-α) has been shown to adversely affect cognitive functioning in patients with a variety of medical disorders, but information about the effects of IFN-α on cognitive functioning in patients with chronic hepatitis C (CHC) is limited. The purpose of this study was t...
Gespeichert in:
| Veröffentlicht in: | Journal of the International Neuropsychological Society 2005-01, Vol.11 (1), p.16-22 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 22 |
|---|---|
| container_issue | 1 |
| container_start_page | 16 |
| container_title | Journal of the International Neuropsychological Society |
| container_volume | 11 |
| creator | HILSABECK, ROBIN C. HASSANEIN, TAREK I. ZIEGLER, ELIZABETH A. CARLSON, MEGHAN D. PERRY, WILLIAM |
| description | Treatment with interferon-alpha (IFN-α) has been shown to
adversely affect cognitive functioning in patients with a variety of
medical disorders, but information about the effects of IFN-α on
cognitive functioning in patients with chronic hepatitis C (CHC) is
limited. The purpose of this study was to examine the effects of
IFN-α on neuropsychological test performance in CHC patients.
Participants were 30 patients with CHC, 11 who underwent IFN-α
therapy and 19 who did not. All participants were tested at baseline
(i.e., pretreatment) and approximately 6 months later with the Symbol
Digit Modalities Test and Trail Making Test. Results revealed that the
treatment group performed significantly worse than untreated CHC
patients on Part B of the Trail Making Test after approximately 6
months of treatment. No significant group differences were found on
Part A of the Trail Making Test or Symbol Digit Modalities Test.
Findings suggest that CHC patients undergoing treatment with IFN-α
may experience reduced abilities to benefit from practice but suffer no
decrements in performance after 6 months of treatment. Additional
research is needed to replicate these findings and to explore risk
factors for susceptibility to IFN-α-induced effects.
(JINS, 2005, 11, 16–22.) |
| doi_str_mv | 10.1017/S1355617705050022 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67397195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S1355617705050022</cupid><sourcerecordid>20213539</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-60de197c99758fdb2c05eea5198d44ff25910da3c5d64b8ed4c38f2da174590f3</originalsourceid><addsrcrecordid>eNqFkMFuVCEYhYmxsbX6AG4MK3dXgXuBy9JM2tpkEmO1a8LAzwx1BkbgVn0sX8RnkpuZ6KJJDQsI5zsnJwehV5S8pYTKd59pz7mgUhLeDmHsCTqjg1CdFII-be8md7N-ip6XckcI7Skhz9Ap5WIUggxn6PbCe7AVJ4-vY4XsIafY_f6FU8Q2rWOo4R6wn6KtIcUQ1zhEvDc1QKwFfw91g-2mWYLFG5j_ayh48QKdeLMt8PJ4n6Pby4sviw_d8uPV9eL9srMDZbUTxAFV0iol-ejdilnCAQynanTD4D3jihJnesudGFYjuMH2o2fOUDlwRXx_jt4ccvc5fZugVL0LxcJ2ayKkqWgheyWp4v8FGWFtrF41kB5Am1MpGbze57Az-aemRM-j6wejN8_rY_i02oH75ziu3IDuAIRS4cdf3eSvc0PJtbj6pNmlVEvOb_Qc2B9LmN0qB7cGfZemHNuUj9T4A103mxo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20213539</pqid></control><display><type>article</type><title>Effect of Interferon-α on cognitive functioning in patients with chronic hepatitis C</title><source>MEDLINE</source><source>Cambridge Journals</source><creator>HILSABECK, ROBIN C. ; HASSANEIN, TAREK I. ; ZIEGLER, ELIZABETH A. ; CARLSON, MEGHAN D. ; PERRY, WILLIAM</creator><creatorcontrib>HILSABECK, ROBIN C. ; HASSANEIN, TAREK I. ; ZIEGLER, ELIZABETH A. ; CARLSON, MEGHAN D. ; PERRY, WILLIAM</creatorcontrib><description>Treatment with interferon-alpha (IFN-α) has been shown to
adversely affect cognitive functioning in patients with a variety of
medical disorders, but information about the effects of IFN-α on
cognitive functioning in patients with chronic hepatitis C (CHC) is
limited. The purpose of this study was to examine the effects of
IFN-α on neuropsychological test performance in CHC patients.
Participants were 30 patients with CHC, 11 who underwent IFN-α
therapy and 19 who did not. All participants were tested at baseline
(i.e., pretreatment) and approximately 6 months later with the Symbol
Digit Modalities Test and Trail Making Test. Results revealed that the
treatment group performed significantly worse than untreated CHC
patients on Part B of the Trail Making Test after approximately 6
months of treatment. No significant group differences were found on
Part A of the Trail Making Test or Symbol Digit Modalities Test.
Findings suggest that CHC patients undergoing treatment with IFN-α
may experience reduced abilities to benefit from practice but suffer no
decrements in performance after 6 months of treatment. Additional
research is needed to replicate these findings and to explore risk
factors for susceptibility to IFN-α-induced effects.
(JINS, 2005, 11, 16–22.)</description><identifier>ISSN: 1355-6177</identifier><identifier>EISSN: 1469-7661</identifier><identifier>DOI: 10.1017/S1355617705050022</identifier><identifier>PMID: 15686604</identifier><language>eng</language><publisher>New York, USA: Cambridge University Press</publisher><subject>Antiviral Agents - therapeutic use ; Chronic liver disease ; Cognition Disorders - drug therapy ; Cognition Disorders - etiology ; Female ; HCV ; Hepatitis C - complications ; Hepatitis C - drug therapy ; Hepatitis C - psychology ; Humans ; Immunologic Factors - therapeutic use ; Interferon-alpha - therapeutic use ; Male ; Middle Aged ; Neuropsychological impairment ; Neuropsychological Tests ; Psychomotor Performance - drug effects ; Treatment Outcome</subject><ispartof>Journal of the International Neuropsychological Society, 2005-01, Vol.11 (1), p.16-22</ispartof><rights>2005 The International Neuropsychological Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-60de197c99758fdb2c05eea5198d44ff25910da3c5d64b8ed4c38f2da174590f3</citedby><cites>FETCH-LOGICAL-c412t-60de197c99758fdb2c05eea5198d44ff25910da3c5d64b8ed4c38f2da174590f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S1355617705050022/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>164,314,780,784,27923,27924,55627</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15686604$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HILSABECK, ROBIN C.</creatorcontrib><creatorcontrib>HASSANEIN, TAREK I.</creatorcontrib><creatorcontrib>ZIEGLER, ELIZABETH A.</creatorcontrib><creatorcontrib>CARLSON, MEGHAN D.</creatorcontrib><creatorcontrib>PERRY, WILLIAM</creatorcontrib><title>Effect of Interferon-α on cognitive functioning in patients with chronic hepatitis C</title><title>Journal of the International Neuropsychological Society</title><addtitle>J Int Neuropsychol Soc</addtitle><description>Treatment with interferon-alpha (IFN-α) has been shown to
adversely affect cognitive functioning in patients with a variety of
medical disorders, but information about the effects of IFN-α on
cognitive functioning in patients with chronic hepatitis C (CHC) is
limited. The purpose of this study was to examine the effects of
IFN-α on neuropsychological test performance in CHC patients.
Participants were 30 patients with CHC, 11 who underwent IFN-α
therapy and 19 who did not. All participants were tested at baseline
(i.e., pretreatment) and approximately 6 months later with the Symbol
Digit Modalities Test and Trail Making Test. Results revealed that the
treatment group performed significantly worse than untreated CHC
patients on Part B of the Trail Making Test after approximately 6
months of treatment. No significant group differences were found on
Part A of the Trail Making Test or Symbol Digit Modalities Test.
Findings suggest that CHC patients undergoing treatment with IFN-α
may experience reduced abilities to benefit from practice but suffer no
decrements in performance after 6 months of treatment. Additional
research is needed to replicate these findings and to explore risk
factors for susceptibility to IFN-α-induced effects.
(JINS, 2005, 11, 16–22.)</description><subject>Antiviral Agents - therapeutic use</subject><subject>Chronic liver disease</subject><subject>Cognition Disorders - drug therapy</subject><subject>Cognition Disorders - etiology</subject><subject>Female</subject><subject>HCV</subject><subject>Hepatitis C - complications</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - psychology</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neuropsychological impairment</subject><subject>Neuropsychological Tests</subject><subject>Psychomotor Performance - drug effects</subject><subject>Treatment Outcome</subject><issn>1355-6177</issn><issn>1469-7661</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFuVCEYhYmxsbX6AG4MK3dXgXuBy9JM2tpkEmO1a8LAzwx1BkbgVn0sX8RnkpuZ6KJJDQsI5zsnJwehV5S8pYTKd59pz7mgUhLeDmHsCTqjg1CdFII-be8md7N-ip6XckcI7Skhz9Ap5WIUggxn6PbCe7AVJ4-vY4XsIafY_f6FU8Q2rWOo4R6wn6KtIcUQ1zhEvDc1QKwFfw91g-2mWYLFG5j_ayh48QKdeLMt8PJ4n6Pby4sviw_d8uPV9eL9srMDZbUTxAFV0iol-ejdilnCAQynanTD4D3jihJnesudGFYjuMH2o2fOUDlwRXx_jt4ccvc5fZugVL0LxcJ2ayKkqWgheyWp4v8FGWFtrF41kB5Am1MpGbze57Az-aemRM-j6wejN8_rY_i02oH75ziu3IDuAIRS4cdf3eSvc0PJtbj6pNmlVEvOb_Qc2B9LmN0qB7cGfZemHNuUj9T4A103mxo</recordid><startdate>200501</startdate><enddate>200501</enddate><creator>HILSABECK, ROBIN C.</creator><creator>HASSANEIN, TAREK I.</creator><creator>ZIEGLER, ELIZABETH A.</creator><creator>CARLSON, MEGHAN D.</creator><creator>PERRY, WILLIAM</creator><general>Cambridge University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><scope>8BM</scope></search><sort><creationdate>200501</creationdate><title>Effect of Interferon-α on cognitive functioning in patients with chronic hepatitis C</title><author>HILSABECK, ROBIN C. ; HASSANEIN, TAREK I. ; ZIEGLER, ELIZABETH A. ; CARLSON, MEGHAN D. ; PERRY, WILLIAM</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-60de197c99758fdb2c05eea5198d44ff25910da3c5d64b8ed4c38f2da174590f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Chronic liver disease</topic><topic>Cognition Disorders - drug therapy</topic><topic>Cognition Disorders - etiology</topic><topic>Female</topic><topic>HCV</topic><topic>Hepatitis C - complications</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - psychology</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neuropsychological impairment</topic><topic>Neuropsychological Tests</topic><topic>Psychomotor Performance - drug effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HILSABECK, ROBIN C.</creatorcontrib><creatorcontrib>HASSANEIN, TAREK I.</creatorcontrib><creatorcontrib>ZIEGLER, ELIZABETH A.</creatorcontrib><creatorcontrib>CARLSON, MEGHAN D.</creatorcontrib><creatorcontrib>PERRY, WILLIAM</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><collection>ComDisDome</collection><jtitle>Journal of the International Neuropsychological Society</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HILSABECK, ROBIN C.</au><au>HASSANEIN, TAREK I.</au><au>ZIEGLER, ELIZABETH A.</au><au>CARLSON, MEGHAN D.</au><au>PERRY, WILLIAM</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Interferon-α on cognitive functioning in patients with chronic hepatitis C</atitle><jtitle>Journal of the International Neuropsychological Society</jtitle><addtitle>J Int Neuropsychol Soc</addtitle><date>2005-01</date><risdate>2005</risdate><volume>11</volume><issue>1</issue><spage>16</spage><epage>22</epage><pages>16-22</pages><issn>1355-6177</issn><eissn>1469-7661</eissn><abstract>Treatment with interferon-alpha (IFN-α) has been shown to
adversely affect cognitive functioning in patients with a variety of
medical disorders, but information about the effects of IFN-α on
cognitive functioning in patients with chronic hepatitis C (CHC) is
limited. The purpose of this study was to examine the effects of
IFN-α on neuropsychological test performance in CHC patients.
Participants were 30 patients with CHC, 11 who underwent IFN-α
therapy and 19 who did not. All participants were tested at baseline
(i.e., pretreatment) and approximately 6 months later with the Symbol
Digit Modalities Test and Trail Making Test. Results revealed that the
treatment group performed significantly worse than untreated CHC
patients on Part B of the Trail Making Test after approximately 6
months of treatment. No significant group differences were found on
Part A of the Trail Making Test or Symbol Digit Modalities Test.
Findings suggest that CHC patients undergoing treatment with IFN-α
may experience reduced abilities to benefit from practice but suffer no
decrements in performance after 6 months of treatment. Additional
research is needed to replicate these findings and to explore risk
factors for susceptibility to IFN-α-induced effects.
(JINS, 2005, 11, 16–22.)</abstract><cop>New York, USA</cop><pub>Cambridge University Press</pub><pmid>15686604</pmid><doi>10.1017/S1355617705050022</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-6177 |
| ispartof | Journal of the International Neuropsychological Society, 2005-01, Vol.11 (1), p.16-22 |
| issn | 1355-6177 1469-7661 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67397195 |
| source | MEDLINE; Cambridge Journals |
| subjects | Antiviral Agents - therapeutic use Chronic liver disease Cognition Disorders - drug therapy Cognition Disorders - etiology Female HCV Hepatitis C - complications Hepatitis C - drug therapy Hepatitis C - psychology Humans Immunologic Factors - therapeutic use Interferon-alpha - therapeutic use Male Middle Aged Neuropsychological impairment Neuropsychological Tests Psychomotor Performance - drug effects Treatment Outcome |
| title | Effect of Interferon-α on cognitive functioning in patients with chronic hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T10%3A49%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Interferon-%CE%B1%20on%20cognitive%20functioning%20in%20patients%20with%20chronic%20hepatitis%20C&rft.jtitle=Journal%20of%20the%20International%20Neuropsychological%20Society&rft.au=HILSABECK,%20ROBIN%20C.&rft.date=2005-01&rft.volume=11&rft.issue=1&rft.spage=16&rft.epage=22&rft.pages=16-22&rft.issn=1355-6177&rft.eissn=1469-7661&rft_id=info:doi/10.1017/S1355617705050022&rft_dat=%3Cproquest_cross%3E20213539%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20213539&rft_id=info:pmid/15686604&rft_cupid=10_1017_S1355617705050022&rfr_iscdi=true |